Head-to-Head Comparisons on B/F/TAF Compared With Other HIV Regimens

Opinion
Video

Sorana Segal-Maurer, MD, reviews research evaluating the efficacy of B/F/TAF compared with other HIV treatment regimens, including dolutegravir plus tenofovir/FTC.

BIC = bictegravir

DRV = darunavir

DTG = dolutegravir

F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide

F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate

B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)

DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)

D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)

CAB = Cabotegravir

CAB + RPV = Cabotegravir + Rilpivirine

Video content above is prompted by the following question(s):

  • Studies have run head-to-head comparisons on the efficacy of B/F/TAF compared to other regimens, like dolutegravir + tenofovir/FTC, stressing patient adherence and the outcomes associated.
    • What are the notable differences in efficacy were seen in these studies?

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.